Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy

References

• Kim D, Xue JY, Lito LP. Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients. Cell. 2020;183(4):850–859.
   PubMed Web of Science ®Google Scholar
• Moore AR, Rosenberg SC, McCormick F, et al. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19(8):533–552.
   PubMed Web of Science ®Google Scholar
• Johnson C, Burkhart DL, Haigis KM. Classification of KRAS-activating mutations and the implications for therapeutic intervention. Cancer Discov. 2022;12(4):913–923.
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548–551.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371–2381.
   PubMed Web of Science ®Google Scholar
• MM A, Liu S, Rybkin II, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384(25):2382–2393.
   PubMed Web of Science ®Google Scholar
• Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309.
   PubMed Web of Science ®Google Scholar
• Romero D. Uncovering adagrasib resistance. Nat Rev Clin Oncol. 2021;18(9):541.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Lin JJ, Li C, et al. Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 2021;11(8):1913–1922.
   PubMed Web of Science ®Google Scholar
• Vasta JD, Peacock DM, Zheng Q, et al. KRAS is vulnerable to reversible switch-II pocket engagement in cells. Nat Chem Biol. 2022;18(6):596–604.
   PubMed Web of Science ®Google Scholar
• Crunkhorn CS. Targeting KRAS with reversible inhibitors. Nat Rev Drug Discov. 2022;21(5):338.
   Google Scholar
• Akhave NS, Biter AB, Hong DS. Mechanisms of resistance to KRAS(G12C)-targeted therapy. Cancer Discov. 2021;11(6):1345–1352.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang J, Liu Q, et al. Resistance looms for KRAS G12C inhibitors and rational tackling strategies. Pharmacol Ther. 2022;229:108050.
   PubMed Web of Science ®Google Scholar
• Arbour KC, Rizvi H, Plodkowski AJ, et al. Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung Cancer. Clin Cancer Res. 2021;27(8):2209–2215.
   PubMed Web of Science ®Google Scholar
• Judd J, Abdel Karim N, Khan H, et al. Characterization of KRAS mutation subtypes in non-small cell lung cancer. Mol Cancer Ther. 2021;20(12):2577–2584.
   PubMed Web of Science ®Google Scholar
• Lanman BA, Allen JR, Allen JG, et al. Discovery of a Covalent Inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors. J Med Chem. 2020;63(1):52–65.
   PubMed Web of Science ®Google Scholar
• Fell JB, Fischer JP, Baer BR, et al. Identification of the clinical development candidate MRTX849, a covalent KRAS(G12C) inhibitor for the treatment of cancer. J Med Chem. 2020;63(13):6679–6693.
   PubMed Web of Science ®Google Scholar
• Ou SI, Janne PA, Leal TA, et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40(23):2530–2538.
   PubMed Web of Science ®Google Scholar
• Ganguly A, Yoo E. Sotorasib: a KRAS(G12C) inhibitor for non-small cell lung cancer. Trends Pharmacol Sci. 2022;43(6):536–537.
   PubMed Web of Science ®Google Scholar
• Moore AR, Malek S. The promise and peril of KRAS G12C inhibitors. Cancer Cell. 2021;39(8):1059–1061.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Chhoeu C, Li J, et al. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature. 2022;603(7900):335–342.
   PubMedGoogle Scholar
• Adachi Y, Ito K, Hayashi Y, et al. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. Clin Cancer Res. 2020;26(22):5962–5973.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Murciano-Goroff YR, Xue JY, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021;599(7886):679–683.
   PubMed Web of Science ®Google Scholar
• Tsai YS, Woodcock MG, Azam SH, et al. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. J Clin Invest. 2022;132(4):e155523.
   PubMed Web of Science ®Google Scholar
• Feng S, Callow MG, Fortin JP, et al. A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRAS(G12C) inhibitors. Proc Natl Acad Sci U S A. 2022;119(18):e2120512119.
   PubMed Web of Science ®Google Scholar
• Xue JY, Zhao Y, Aronowitz J, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577(7790):421–425.
   PubMed Web of Science ®Google Scholar
• Ryan MB, Fece de la Cruz F, Phat S, et al. Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition. Clin Cancer Res. 2020;26(7):1633–1643.
   PubMed Web of Science ®Google Scholar
• Misale S, Fatherree JP, Cortez E, et al. KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition. Clin Cancer Res. 2019;25(2):796–807.
   PubMed Web of Science ®Google Scholar
• Hofmann MH, Gmachl M, Ramharter J, et al. BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 2021;11(1):142–157.
   PubMed Web of Science ®Google Scholar
• Hofmann MH, Gerlach D, Misale S, et al. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov. 2022;12(4):924–937.
   PubMed Web of Science ®Google Scholar
• Ahmed TA, Adamopoulos C, Karoulia Z, et al. SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors. Cell Rep. 2019;26(1):65–78 e5.
   PubMed Web of Science ®Google Scholar
• Weiss A, Lorthiois E, Barys L, et al. Discovery, preclinical Characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12C. Cancer Discov. 2022;12(6):1500–1517.
   PubMed Web of Science ®Google Scholar
• Fedele C, Li S, Teng KW, et al. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. J Exp Med. 2021;218(1):e20201414.
   PubMed Web of Science ®Google Scholar
• Sun C, Bernards R. Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies. Trends Biochem Sci. 2014;39(10):465–474.
   PubMed Web of Science ®Google Scholar
• Lito P, Solomon M, Li LS, et al. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351(6273):604–608.
   PubMed Web of Science ®Google Scholar
• Yaeger R, Solit DB. Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting. Clin Cancer Res. 2020;26(7):1538–1540.
   PubMed Web of Science ®Google Scholar
• Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–223.
   PubMed Web of Science ®Google Scholar
• Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10(1):54–71.
   PubMed Web of Science ®Google Scholar
• Qian D, Behera M, Steuer CE, et al. KRAS G12C mutation associated outcomes among patients with locally advanced non-small cell lung cancer. J Clin Oncol. 2020;38(15):e21079–e21079.
   Google Scholar
• Tani T, Kitajima S, Conway EB, et al. KRAS G12C inhibition and innate immune targeting. Expert Opin Ther Targets. 2021;25(3):167–174.
   PubMed Web of Science ®Google Scholar
• Kerk SA, Papagiannakopoulos T, Shah YM, et al. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nat Rev Cancer. 2021;21(8):510–525.
   PubMed Web of Science ®Google Scholar
• Manabe T, Bivona TG. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer. J Clin Invest. 2022;132(4):e156891.
   PubMed Web of Science ®Google Scholar
• Briere DM, Calinisan A, Aranda R, et al. Abstract LB-C09: the KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model. Mol Cancer Ther. 2019;2019(18):LB–C09.
   Google Scholar
• Khan S, Wiegand J, Zhang P, et al. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers. J Hematol Oncol. 2022;15(1):23.
   PubMed Web of Science ®Google Scholar
• Zeng M, Xiong Y, Safaee N, et al. Exploring targeted degradation strategy for oncogenic KRAS(G12C). Cell Chem Biol. 2020;27(1):19–31 e6.
   PubMed Web of Science ®Google Scholar
• Bond MJ, Chu L, Nalawansha DA, et al. Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs. ACS Cent Sci. 2020;6(8):1367–1375.
   PubMed Web of Science ®Google Scholar